The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

Big pharma is no stranger to controversy, and AbbVie is perhaps one of the most lambasted.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Humira: lessons from 20 years of patents, pricing and profits

21 March 2023 As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

Generics

Abbvie seeks to block copycat of endometriosis drug

4 April 2023 Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.

Americas

FTC weighs in on AbbVie antitrust litigation

22 June 2023 Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.

More on this story

Big Pharma

Humira: lessons from 20 years of patents, pricing and profits

21 March 2023 As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

Generics

Abbvie seeks to block copycat of endometriosis drug

4 April 2023 Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.

Americas

FTC weighs in on AbbVie antitrust litigation

More on this story

Big Pharma

Humira: lessons from 20 years of patents, pricing and profits

21 March 2023 As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

Generics

Abbvie seeks to block copycat of endometriosis drug

4 April 2023 Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.

Americas

FTC weighs in on AbbVie antitrust litigation